The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 18 rounds in the feed, most often in Biotech.
Corporate venture armpfizer.comRounds from 2014-09-22 to 2026-06-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ PART ] |
CellCentric A drug-discovery platform |
| $220M |
| 2026-05-06 |
| [ PART ] |
STORM Therapeutics STORM Therapeutics develops RNA modifying enzyme inhibitors for the treatment of sarcomas. | Series C Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $56M | 2026-04-16 | [ PART ] |
OTR Therapeutics OTR Therapeutics focuses on discovering and acquiring preclinical assets to develop innovative therapies for patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-12-05 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-03 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
CellCentric A drug-discovery platform | Funding round Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2024-07-24 | [ PART ] |
CellCentric A drug-discovery platform | Strategic investment Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $25M | 2023-07-11 | [ LEAD ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | [ LEAD ] |
STORM Therapeutics STORM Therapeutics develops RNA modifying enzyme inhibitors for the treatment of sarcomas. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2022-12-14 | [ LEAD ] |
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65M | 2022-06-14 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2022-04-06 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
STORM Therapeutics STORM Therapeutics develops RNA modifying enzyme inhibitors for the treatment of sarcomas. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $17.8M | 2019-05-20 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2018-08-10 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $4.5M | 2016-12-21 | [ PART ] |
STORM Therapeutics STORM Therapeutics develops RNA modifying enzyme inhibitors for the treatment of sarcomas. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $16.1M | 2016-06-28 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Seed Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | n/a | 2014-09-22 | [ PART ] |